Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review and Meta-Analysis of Evidence-Based Management Options
Tóm tắt
Early non-response is a well-established prognostic marker but evidence-based and consistent recommendations to manage it are limited. The aim of this systematic review and meta-analysis was to generate evidence-based strategies for the management of schizophrenia patients with early non-response to 2 weeks of antipsychotic treatment. We conducted a systematic review and meta-analysis of randomized trials comparing antipsychotic dose escalation, switch, augmentation and continuation in individuals with study-defined early antipsychotic treatment non-response. Eligibility criteria were (1) clinical trials of primary psychosis treating for at least 2 weeks with antipsychotic monotherapy with study-defined operationalized criteria for early non-response; and (2) randomization to at least two of the following treatment strategies: dose escalation, switch, augmentation, or treatment continuation. Information sources were Pubmed, PsycINFO, and EMBASE, and risk of bias was assessed using Jadad scores. Results were synthesized using random-effects meta-analysis, comparing each intervention with treatment continuation for total symptom change as the primary outcome, generating standardized mean differences (SMDs) and 95% confidence intervals (CIs). Studies meeting the selection criteria but providing insufficient data for a meta-analysis were presented separately. We screened 454 records by 1 August 2022, of which 12 individual datasets met the inclusion criteria, representing 947 research participants. Of those studies, five provided data to include in the meta-analysis (four with early non-response at 2 weeks, one at 3 weeks). Early non-response was defined within a timeline of 2 weeks in eight datasets, with the remaining datasets ranging between 3 and 4 weeks. The rates of early non-response ranged between 72.0 and 24.1%, and the endpoint ranged within 4–24 weeks post randomization. Quality was good (i.e., Jadad score of ≥3) in 8 of the 12 datasets. Overall, three studies compared antipsychotic switch versus continuation and two compared antipsychotic switch versus augmentation, in both cases without significant pooled between-group differences for total symptom severity (n = 149, SMD 0.18, 95% CI −0.14 to 0.5). Individually, two relatively large studies for antipsychotic switch versus continuation found small advantages for switching antipsychotics for total symptom severity (n = 149, SMD −0.49, 95% CI −1.05 to −0.06). One relatively large study found an advantage for dose escalation, although this finding has not been replicated and was not included in the meta-analysis. None of the alternatives included antipsychotic switch to clozapine. Despite robust accuracy of early antipsychotic non-response predicting ultimate response, the evidence for treatment strategies that should be used for early non-response after 2–3 weeks is limited. While meta-analytic findings were non-significant, some individual studies suggest advantages of antipsychotic switch or dose escalation. Therefore, any conclusions should be interpreted carefully, given the insufficient high-quality evidence.
Tài liệu tham khảo
Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of Schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195–203. https://doi.org/10.1093/schbul/sby058.
Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primer. 2015;2:15067. https://doi.org/10.1038/nrdp.2015.67.
McCutcheon RA, Pillinger T, Efthimiou O, et al. Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis. World Psychiatry. 2022;21(2):287–94. https://doi.org/10.1002/wps.20977.
Winkelbeiner S, Leucht S, Kane JM, Homan P. Evaluation of differences in individual treatment response in schizophrenia spectrum disorders: a meta-analysis. JAMA Psychiat. 2019;76(10):1063–73. https://doi.org/10.1001/jamapsychiatry.2019.1530.
Sarpal DK, Argyelan M, Robinson DG, et al. Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. Am J Psychiatry. 2016;173(1):69–77. https://doi.org/10.1176/appi.ajp.2015.14121571.
Li A, Zalesky A, Yue W, et al. A neuroimaging biomarker for striatal dysfunction in schizophrenia. Nat Med. 2020;26(4):558–65. https://doi.org/10.1038/s41591-020-0793-8.
Samara MT, Leucht C, Leeflang MM, et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry. 2015;172(7):617–29. https://doi.org/10.1176/appi.ajp.2015.14101329.
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005;79(2–3):231–8. https://doi.org/10.1016/j.schres.2005.04.008.
Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604–16. https://doi.org/10.1177/0706743717720448.
Keepers GA, Fochtmann LJ, Anzia JM, et al. The American psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–72. https://doi.org/10.1176/appi.ajp.2020.177901.
Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318–78. https://doi.org/10.3109/15622975.2012.696143.
Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008;69(Suppl 1):4–17.
Kahn RS, van Winter RI, Leucht S, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry. 2018;5(10):797–807. https://doi.org/10.1016/S2215-0366(18)30252-9.
Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiat. 2017;74(7):675–84. https://doi.org/10.1001/jamapsychiatry.2017.0624.
Galling B, Roldán A, Hagi K, Rietschel L, Walyzada F, Zheng W, et al. Antipsychotic augmentation vs monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017;16(1):77–89.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097. https://doi.org/10.1371/journal.pmed.1000097.
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. https://doi.org/10.1016/0197-2456(95)00134-4.
R Core Team (2020). R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. URL https://www.R-project.org/.
Suzuki T, Uchida H, Watanabe K, et al. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone? A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology. 2007;195(2):285–95. https://doi.org/10.1007/s00213-007-0872-2.
Kinon BJ, Kane JM, Johns C, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull. 1993;29(2):309–14.
Shalev A, Hermesh H, Rothberg J, Munitz H. Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatr Scand. 1993;87(2):86–91. https://doi.org/10.1111/j.1600-0447.1993.tb03335.x.
Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacol. 2010;35(2):581–90. https://doi.org/10.1038/npp.2009.164.
Heres S, Cordes J, Feyerabend S, et al. Changing the antipsychotic in early nonimprovers to amisulpride or olanzapine: randomized, double-blind trial in patients with schizophrenia. Schizophr Bull. 2022;48(6):1273–83. https://doi.org/10.1093/schbul/sbac068.
Loebel A, Silva R, Goldman R, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized placebo-controlled study. J Clin Psychiatry. 2016;77(12):1672–80. https://doi.org/10.4088/JCP.16m10698.
Hatta K, Otachi T, Sudo Y, et al. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone. Psychiatry Res. 2012;198(2):194–201. https://doi.org/10.1016/j.psychres.2012.01.006.
Hatta K, Otachi T, Fujita K, et al. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia. Schizophr Res. 2014;158(1–3):213–22. https://doi.org/10.1016/j.schres.2014.07.015.
Correll CU, Martin A, Patel C, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. NPJ Schizophr. 2022;8(1):5. https://doi.org/10.1038/s41537-021-00192-x.
Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216–29. https://doi.org/10.1176/appi.ajp.2016.16050503.
Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(Suppl 3):1–24. https://doi.org/10.4088/JCP.15032su1.
Lopez LV, Shaikh A, Merson J, Greenberg J, Suckow RF, Kane JM. Accuracy of clinician assessments of medication status in the emergency setting: a comparison of clinician assessment of antipsychotic usage and plasma level determination. J Clin Psychopharmacol. 2017;37(3):310–4. https://doi.org/10.1097/JCP.0000000000000697.
McCutcheon R, Beck K, D’Ambrosio E, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand. 2018;137(1):39–46. https://doi.org/10.1111/acps.12825.
Rubio JM, Schoretsanitis G, John M, et al. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. Lancet Psychiatry. 2020;7(9):749–61. https://doi.org/10.1016/S2215-0366(20)30264-9.
Bak M. Monitoring clozapine adverse effects calls for the integration of protocol and good clinical practice. J Clin Psychiatry. 2012;73(10):1313–4. https://doi.org/10.4088/JCP.12com07964.
Kane JM, Agid O, Baldwin ML, et al. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. J Clin Psychiatry. 2019;80(2):18123. https://doi.org/10.4088/JCP.18com12123.
Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol. 2012;32(5):678–83. https://doi.org/10.1097/JCP.0b013e318267b3cd.
Thien K, O’Donoghue B. Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: a literature review. Early Interv Psychiatry. 2019;13(1):18–23. https://doi.org/10.1111/eip.12683.
Bachmann CJ, Aagaard L, Bernardo M, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136(1):37–51. https://doi.org/10.1111/acps.12742.
Bareis N, Olfson M, Wall M, Stroup TS. Variation in psychotropic medication prescription for adults with schizophrenia in the United States. Psychiatr Serv. 2022;73(5):492–500. https://doi.org/10.1176/appi.ps.202000932.
Potkin SG, Kane JM, Correll CU, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020;6(1):1. https://doi.org/10.1038/s41537-019-0090-z.
Koutsouleris N, Kambeitz-Ilankovic L, Ruhrmann S, et al. Prediction models of functional outcomes for individuals in the clinical high-risk state for psychosis or with recent-onset depression: a multimodal, multisite machine learning analysis. JAMA Psychiat. 2018;75(11):1156. https://doi.org/10.1001/jamapsychiatry.2018.2165.
Gallego JA, Robinson DG, Sevy SM, et al. Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? J Clin Psychiatry. 2011;72(12):1691–6. https://doi.org/10.4088/JCP.10m06349.
Case M, Stauffer VL, Ascher-Svanum H, et al. The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychol Med. 2011;41(6):1291–300. https://doi.org/10.1017/S0033291710001893.
Ketter TA, Agid O, Kapur S, Loebel A, Siu CO, Romano SJ. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. J Psychiatr Res. 2010;44(1):8–14. https://doi.org/10.1016/j.jpsychires.2009.07.006.
Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60(12):1228–35. https://doi.org/10.1001/archpsyc.60.12.1228.
Schoretsanitis G, Kane JM, Correll CU, et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the american society of clinical psychopharmacology and the therapeutic drug monitoring task force of the arbeitsgemeinschaft für neuropsychopharmakologie und pharmakopsychiatrie. J Clin Psychiatry. 2020;81(3):199. https://doi.org/10.4088/JCP.19cs13169.
Woo YS, Park SY, Yoon BH, Choi WS, Wang SM, Bahk WM. Amisulpride augmentation in schizophrenia patients with poor response to olanzapine: a 4-week, randomized, rater-blind, controlled Pilot Study. Clin Psychopharmacol Neurosci. 2022;20(3):567–72. https://doi.org/10.9758/cpn.2022.20.3.567.
Hatta K, Otachi T, Sudo Y, et al. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Schizophr Res. 2011;128(1–3):127–35. https://doi.org/10.1016/j.schres.2011.02.011.
Loebel A, Citrome L, Correll CU, Xu J, Cucchiaro J, Kane JM. Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. BMC Psychiatry. 2015;15:271. https://doi.org/10.1186/s12888-015-0629-0.